News & Updates
Filter by Specialty:
KangDuo Surgical Robot-01 system feasible for robot-assisted radical prostatectomy
Use of the KangDuo Surgical Robot-01 (KD-SR-01) system for the management of localized prostate cancer is safe and effective, according to the initial results of a prospective, single-centre study.
KangDuo Surgical Robot-01 system feasible for robot-assisted radical prostatectomy
24 Jun 2022
Negative transrectal ultrasound biopsy tied to low prostate cancer death
Prostate cancer-specific mortality is very low among men with negative transrectal ultrasound (TRUS) biopsies, particularly those with prostate-specific antigen (PSA) <10 ng/ml, reports a study.
Negative transrectal ultrasound biopsy tied to low prostate cancer death
23 Jun 2022
Rare gene mutations predict prostate cancer relapse
Rare and deleterious germline mutations affecting inflammatory response and cellular signaling pathways associate strongly with the time to biochemical recurrence (BCR) after radical treatment in patients with prostate cancer (PrCa), according to a recent study.
Rare gene mutations predict prostate cancer relapse
23 Jun 2022
Depression, sleep disturbance tied to urinary symptoms in men with LUTS
In men with lower urinary tract symptoms (LUTS), urinary symptom subdomains show an independent association with modifiable clinical variables such as sleep quality and depression at all time points, a study has found. However, these variables do not predict the degree of improvement in LUTS after assessment and treatment over the medium term.
Depression, sleep disturbance tied to urinary symptoms in men with LUTS
22 Jun 2022
What causes death in bladder cancer patients?
Heart diseases, chronic obstructive pulmonary disease (COPD), concomitant cancers, and other co-occurring diseases elevate the risk of death in patients with nonmuscular invasive bladder cancer (NMIBC), nonmetastatic muscle invasive bladder cancer (non-MMIBC), and metastatic bladder cancer (MBC), according to a recent study.
What causes death in bladder cancer patients?
22 Jun 2022
Nintedanib falls short in bladder cancer trial
In the phase II NEOBLADE* trial, the addition of the multikinase** inhibitor nintedanib to neoadjuvant chemotherapy (CT) consisting of gemcitabine and cisplatin failed to improve pathological complete response (pCR) and progression-free survival (PFS) in individuals with locally advanced muscle-invasive bladder cancer (MIBC).
Nintedanib falls short in bladder cancer trial
21 Jun 2022
HoLEP, RASP deliver equally excellent postoperative outcomes in benign prostatic hyperplasia
The use of holmium laser enucleation of the prostate (HoLEP) and robotic-assisted simple prostatectomy (RASP) deliver comparable and good postoperative outcomes in patients with large benign prostatic hyperplasia (BPH), a new study has found.